Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this prospective study is to evaluate the degree of post-inflammatory
pigmentation alteration on legs of study subjects treated with two different psoriasis
treatments. Betamethasone dipropionate 0.05% cream is a high potency steroid that is commonly
used to alleviate the inflammation of psoriasis. Tapinarof is another medication approved for
psoriasis; tapinarof activates aryl hydrocarbon receptors to downregulate inflammatory
cytokines (such as interleukin [IL]-17) which play a large role in psoriasis. Study subjects
will be randomized to receive one of these medications and will be followed to monitor for
PIPA. Photographs will be taken to help evaluate visual changes. The Taylor Hyperpigmentation
scale will be used to grade the area and severity of hyperpigmentation and hypopigmentation;
severity of erythema, burning, peeling, and dryness will also be recorded. This will allow us
to understand the effects of two standard-of-care psoriasis medications to better treat
patients.